PSY24 Pregabalin is Cost-Saving in Comparison with Gabapentin Treated Patients when Added to Existing Therapy in the Management of Painful Radiculopathies  by Sicras-Mainar, A. et al.
1Internal Medecine Department, La Pitié Salpétrière Hospital, Paris, France, 2Internal Medecine
Department, Robert Debré Hospital, Reims, France, 3Internal Medecine Department, Hôtel Dieu
Hospital, Nantes, France, 4Internal Medecine and Rheumatology Department, Fort de France
Hospital, Fort de France, France, 5Internal Medecine Department, Pellegrin Hospital, Bordeaux,
France, 6Internal Medecine Department, Hurriez Hospital, Lille, France, 7Nephrology and Clinical
Immunology Department, Rangueil Hospital, Toulouse, France, 8Internal Medecine Department,
l’Archet Hospital, Nice, France, 9Glaxo Smith Kline, Marly-le-Roi, France, 10IMS Health, Puteaux,
France
OBJECTIVES: To determine the annual direct medical cost of the management of
adult patient with active antinuclear autoantibody positive SLE. METHODS: LUCIE
is a multicenter, observational, retrospective study carried out in five European
countries, including France. SLE patients characteristics, disease severity (severe
patient defined as having at least one major domain actively involved at inclusion:
renal, neurological, cardiovascular or respiratory AND Requiring corticosteroids 
7.5 mg/day and/or immunosuppressants), flares rate, health care consumption
(laboratory tests, biopsies and/or imaging tests, medications, specialist visit, hos-
pitalisations) were collected retrospectively over a two-years period. The French
national health insurance perspective was considered when estimating the aver-
age annual direct cost using official cost database. Major cost drivers associated
with SLE and flares management were identified by multivariate regression
models. RESULTS: Eight French SLE centres participated in the study, and included
96 consecutive patients: mean age 39.911.9 years, 93.5% females. The mean SLE
duration was 9.86.6 years, the mean SELENA-SLEDAI score, a semiquantitative
index of SLE activity was 7.75.1. On average, SLE patients had 1.10.59 flares/year.
The annual unadjusted mean direct medical cost of SLE patients was €4116
(SD5498). In severe patients the cost was 1.3 times higher: €4660 versus €3560 in
non-severe patients (NS). Medical treatment represents the largest component of
the average annual direct cost of SLE patients (61.8%) and was higher in severe
patients (7214€ versus 1855€, p0.030). Biological drugs, even though prescribed to
only 10.8% of patients, represented 3.4% of the annual total medical treatment cost.
The multivariate regression model showed that each severe flare increases cost by
€1230 (p0.2). CONCLUSIONS: The annual direct medical cost of active SLE is sig-
nificant especially for patients experiencing severe flare and is mostly driven by the
cost of medication.
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OBJECTIVES: Medication adherence and persistence are important in the treat-
ment of fibromyalgia. The objective of this study is to examine the predictors of
adherence and persistence to duloxetine therapy among commercially-insured
fibromyalgia patients. METHODS: This study analyzed medical and pharmacy re-
cords for commercially-insured patients aged 18-64 with fibromyalgia who initi-
ated (no prior 90-day use) duloxetine in 2008. Patients selected had continuous
health insurance enrollment for 12 months preceding and following duloxetine
initiation, at least 1 fibromyalgia diagnosis during the 12 months before, or 1 month
after, the initiation date, and at least 30-day cumulative duloxetine supply over the
12-month post-index period. Adherence to duloxetine was measured by medica-
tion possession ratio (MPR  post 1-year total duloxetine supply days/365), with
high adherence defined as MPR 0.8. Persistence was defined as the length of
therapy (LOT) from the index date to the earliest of the ending date of the last
prescription, the date of the first gap of more than 15 days between prescriptions,
or the end of study period (12 months). Demographic and clinical predictors of
adherence and persistence were examined via multivariate logistic regression
(MLR) and classification and regression trees (CART). RESULTS: Among 4,660 du-
loxetine patients, 33% achieved high adherence. Factors associated with high ad-
herence from MLR included older age, North Central and Northeast regions, prior
venlafaxine, pregabalin, SSRIs or other antidepressants use, or comoribid dyslipi-
demia, osteoarthritis, or skin and subcutaneous tissue disorders (all p0.05). CART
analysis revealed that patients with prior use of antidepressants, age 46, or prior
osteoarthritis disorder had higher MPR (all p0.05), and patients aged 45 with a
history of SSRI, venlafaxine or anticonvulsant use had longer LOT (all p0.05).
CONCLUSIONS: One-third of fibromyalgia patients on duloxetine achieved high
adherence. Patients with high adherence and persistence to duloxetine were sig-
nificantly older and had prior antidepressant use.
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OBJECTIVES: To compare the costs of adding pregabalin or gabapentin to existing
therapy in patients with peripheral neuropathic pain (PNeP) in routine medical
practice in a Spanish setting. METHODS: A retrospective database analysis was
performed using patients’ medical claims records. Medical records from male and
female patients, with PNeP, 18 years, in whom pregabalin, or gabapentin was
initiated between 2006 and 2008 were included in the analysis. The economic
model included health care resource utilization and corresponding costs, from a
third-payer perspective. Estimates of indirect costs, due to sick leave were
included. RESULTS: A total of 1160 records were eligible for analysis: 764 (65.7%)
treated with pregabalin and 399 (34.3%) gabapentin. Patients in both groups were
comparable. No significant differences were observed for previous average number
of analgesics: pregabalin 2.7 (0.1); gabapentin 2.8 (0.1), p0.362. However, concom-
itant use of analgesics was higher in gabapentin cohort; 3.2 (0.1) versus 2.7 (0.1);
p0.003, mainly due to a higher utilization of NSAIDs (74.9% versus 69.5%; p0.018)
and opioids (27.7% vs. 17.9%; p0.031). Adjusted mean (95% CI) total costs per
patient were significantly lower in pregabalin group; €2514 (2228-2800) versus €3241
(2853-3630); p 0.003, due to minor labour productivity losses; €1067 (790-1345)
versus €1633 (1256-2009); p0.018, and lower adjusted health care costs; €1447
(1380-1513) versus €1609 (1519-1698); p0.004. The higher drug acquisition costs for
pregabalin [€351 versus €191; p0.001) was compensated for by lower overall
health care costs, mainly in medical visits, physiotherapy, hospitalization days and
concomitant analgesics. CONCLUSIONS: In a population setting in Spain, pregaba-
lin treated patients with PNeP were considerable less costly for the healthcare
provider than those treated with gabapentin in routine clinical practice. The higher
acquisition cost of pregabalin was compensated largely by lower costs in the other
components of health care costs. Patients treated with pregabalin had significantly
less sick leaves than gabapentin treated patients.
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OBJECTIVES: Adding pregabalin or gabapentin to existing therapy in patients with
painful radiculopathies in routine medical practice in a Spanish health care setting.
METHODS: A retrospective database analysis was performed using patients’ med-
ical claims records from BSA. Medical records from male and female, with cervical,
dorsal or lumbar painful radiculopathy, 18 years, in whom pregabalin, or gabap-
entin was initiated between 2006 and 2008 were included in the analysis. The
economic analysis included healthcare resource utilization and corresponding
costs from a third-payer perspective. Estimates of indirect costs, due to sick leave
were also included. RESULTS: A total of 571 records were eligible for analysis: 378
(66.2%) treated with pregabalin and 193 (33.8%) gabapentin. Time since diagnosis,
duration of treatment, prevalence of most comorbidities and previous use of anal-
gesics were comparable. However, concomitant use of analgesics was higher in
gabapentin cohort; 3.1 (1.7) versus 2.8 (1.8); p0.05, mainly due to a higher utiliza-
tion of opioids (31.1% vs. 21.2%; p0.05) and non-narcotic (63.7% vs. 52.1%; p0.01)
drugs. Adjusted total costs per patient were significantly lower in pregabalin group;
€2472 (2101-2836) versus. €3346 (2866-3825); p 0.005, due to minor absenteeism
costs; €1012 (658-1365) versus €1595 (1129-2062); p0.042, and lower adjusted
health care costs; €1,460 (1,360-1,560) versus €1750 (1618-1882); p0.001. The higher
drug acquisition costs for pregabalin [€343 vs. €222; p0.001) was largely compen-
sated for by lower overall health care costs, mainly in primary care medical visits,
hospitalization days and concomitant analgesics. CONCLUSIONS: In a population
setting in Spain, pregabalin treated patients with painful radiculopathies were
considerable less costly for the health care provider than those treated with gaba-
pentin in routine clinical practice. The higher acquisition cost of pregabalin was
compensated largely by lower costs in the other components of health care costs.
Patients treated with pregabalin had significantly less sick leaves than gabapentin
treated patients.
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OBJECTIVES: In recent years there has been a large increase in the number of
morbidly obese persons subject to hospital surgery. In Portugal, 14% of the popu-
lation of working age is obese. As in other countries these numbers have been
rising and it is well known that obese individuals have an increased risk of mor-
bidity and premature death from various diseases. We estimate the impact of
obesity on the health sector by calculating the costs of hospital inpatient care
associated with obesity in Portugal. METHODS: A prevalence-based cost of treat-
ment approach is adopted. Hospital episode micro data are drawn from the Na-
tional Health Service’s (NHS) DRG information system for 2008 (n965 212). Besides
episodes where the main diagnosis is obesity, population attributable fractions are
calculated for 16 co-morbidities (CID-9-MC), including diabetes type 2, musculosk-
eletal diseases, cardiovascular conditions and some types of cancer. Relative risks
are drawn from a recent meta-analysis of large-scale prospective studies and prev-
alence data from a nationally representative examination survey that recorded
anthropometric data. Unit cost data are taken from an NHS database. RESULTS:
The hospital inpatient costs of obesity in NHS hospitals in 2008 are estimated as €
85.9 million. This corresponds to 0.92% of annual NHS expenditure. The three
major contributors to this total are osteoarthritis (19.9%), obesity (15.4%) and isch-
emic heart disease (14.7%). If circulatory and cerebrovascular system diagnoses are
grouped together, they become the largest contributors to total costs.
CONCLUSIONS: The structure of costs by diagnosis is different to that commonly
found in ambulatory care. Despite the sharp increase in the number of persons
subject to obesity surgery the overall inpatient care costs have remained largely
stable over time. There has been a large increase in the resources used to treat
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